[Among adults with cardiovascular disease and BMI≥27kg/m2 but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?]

Rev Med Interne. 2024 Mar;45(3):178-179. doi: 10.1016/j.revmed.2024.01.006. Epub 2024 Jan 16.
[Article in French]
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Body Mass Index
  • Cardiovascular Diseases*
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Myocardial Infarction* / drug therapy
  • Myocardial Infarction* / epidemiology
  • Stroke* / prevention & control

Substances

  • semaglutide
  • Hypoglycemic Agents
  • Glucagon-Like Peptides